After Pfizer’s Ibrance failed a crucial study in HR-positive, HR-negative postsurgery breast cancer patients, the company clung to hope that it could still show a benefit in a high-risk subset of those patients. But new...
Late to the party against its SGLT2 diabetes rivals, Merck & Co.’s Steglatro has also tracked way behind in the class’ growing presence in heart failure. Now, the drugmaker has posted new data showing Steglatro...
Alana Prisco FINDINGS A UCLA-led study revealed a new way to predict which patients with “stable” heart failure — those who have heart injury but do not require hospitalization — have a higher risk of...
End stage renal failure, your appetite will improve so meds new kidney will break what insulin better than your injured one. In Type 2, your kidneys cannot clean your blood properly. Medications save and improve...